Scheduling, Location, and Hours of Operation
Extended hours are available for time-sensitive patient care needs. Questions? Contact celltherapyresearch@mcw.edu.
Services and Technologies
The CTSR provides initial review of the project, support of clinical trial design, and grant consultation services, free of charge, to help users understand the technical aspects, advantages, limitations, turnaround time, and cost of services.
iLab Requests; Funding Support
iLab Requests and Support
Funding Support
Investigators should first utilize all available funding resources (below). If funding support is still needed, contact the Shared Resource Director to discuss Cancer Center support.
- Grant Funding (internal or external)
- Cancer Center Pilot Grants
- Start-up Funding
- Departmental Support
Shared Resource Acknowledgement
View Shared Resource acknowledgement instructions. (PDF)
Leadership
Staff Members
Notable Publications
Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma.
(Shah N, Colina A, Johnson B, Szabo A, Furqan F, Kearl T, Schneider D, Vargas-Cortes M, Schmeling J, Dwinell M, Palen K, Longo W, Hematti P, Zamora A, Hari P, Bucklan D, Cunningham A, Hamadani M, Fenske T) J Clin Oncol PMID: 40163793; DOI: 10.1200/JCO-24-02158; Online ahead of print.
Tumor-specific T cells in head and neck cancer have rescuable functionality and can be identified through single-cell co-culture. (Zenga J, Awan M, Frei A, Foeckler J, Kuehn R, Espinosa OV, Bruening J, Massey B, Wong S, Shreenivas A, Shukla M, Kasprzak J, Sun Y, Shaheduzzaman M, Chen F, Kearl T, Himburg HA) Transl Oncol 2024 Apr;42:101899 PMID: 38320395 PMCID: PMC10851216 DOI: 10.1016/j.tranon.2024.101899 SCOPUS ID: 2-s2.0-85184507548 02/07/2024
Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401. (Chung DJ, Shah N, Wu J, Logan B, Bisharat L, Callander N, Cheloni G, Anderson K, Chodon T, Dhakal B, Devine S, Somaiya Dutt P, Efebera Y, Geller N, Ghiasuddin H, Hematti P, Holmberg L, Howard A, Johnson B, Karagkouni D, Lazarus HM, Malek E, McCarthy P, McKenna D, Mendizabal A, Nooka A, Munshi N, O'Donnell L, Rapoport AP, Reese J, Rosenblatt J, Soiffer R, Stroopinsky D, Uhl L, Vlachos IS, Waller EK, Young JW, Pasquini MC, Avigan D) Clin Cancer Res 2023 Dec 01;29(23):4784-4796. DOI: 10.1158/1078-0432.CCR-23-0235. PMID: 37463058; PMCID: PMC10690096 SCOPUS ID: 2-s2.0-85178651085 07/18/23
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. (Bolaños-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, Elmariah H, Rezvani AR, Gooptu M, Larkin KT, Shaffer BC, El Jurdi N, Loren AW, Solh M, Hall AC, Alousi AM, Jamy OH, Perales MA, Yao JM, Applegate K, Bhatt AS, Kean LS, Efebera YA, Reshef R, Clark W, DiFronzo NL, Leifer E, Horowitz MM, Jones RJ, Holtan SG, BMT CTN 1703 Investigators) N Engl J Med 2023 Jun 22;388(25):2338-2348 PMID 37342922 PMCID: PMC10575613 SCOPUS ID: 2-s2.0-85164529275 6/21/2023
Manufacture and Characterization of Good Manufacturing Practice-Compliant SARS-COV-2 Cytotoxic T Lymphocytes. (Chu Y, Milner J, Lamb M, Maryamchik E, Rigot O, Ayello J, Harrison L, Shaw R, Behbehani GK, Mardis ER, Miller K, Prakruthi Rao Venkata L, Chang H, Lee D, Rosenthal E, Kadauke S, Bunin N, Talano JA, Johnson B, Wang Y, Cairo MS) J Infect Dis 2023 Mar 28;227(6):788-799 PMID: 36583990 DOI: 10.1093/infdis/jiac500 SCOPUS ID: 2-s2.0-85151044080 12/31/2022
Associations between socioeconomic status and bispecific LV20.19 CAR T-cell therapy outcomes. (Knight JM, Hackett E, Szabo A, Wu R, Sauber G, Johnson B, Cusatis RN, Aughey E, Cole SW, Hillard CJ, Shah NN) Haematologica 2023 Feb 01;108(2):588-593 PMID: 36200427 PMCID: PMC9890001 SCOPUS ID: 2-s2.0-85147234722 10/07/2022
Long-term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20.19 CAR T-cells. (Zurko JC, Fenske TS, Johnson BD, Bucklan D, Szabo A, Xu H, Chaney K, Hamadani M, Hari P, Shah NN) Am J Hematol 2022 Dec;97(12):1580-1588 PMID: 36068950 DOI: 10.1002/ajh.26718 Scopus ID: 2-s2.0-85138335080 9/08/2022
KIR-favorable TCR-αβ/CD19-depleted haploidentical HCT in children with ALL/AML/MDS: primary analysis of the PTCTC ONC1401 trial. (Pulsipher MA, Ahn KW, Bunin NJ, Lalefar N, Anderson E, Flower A, Cairo MS, Talano JA, Chaudhury S, Kitko CL, Duke JL, Monos D, Leung W, Dvorak CC, Abdel-Azim H) Blood 2022 Dec 15;140(24):2556-2572 PMID: 35776909 PMCID: PMC9918850 SCOPUS ID: 2-s2.0-85144585749 7/02/2022
Black patients with multiple myeloma have better survival than white patients when treated equally. (Dong J, Garacci Z, Buradagunta CS, D'Souza A, Mohan M, Cunningham A, Janz S, Dhakal B, Thrift AP, Hari P) Blood Cancer J. 2022 Feb 24;12(2):34 PMID: 35210395 PMCID: PMC8873507 SCOPUS ID: 2-s2.0-85125303734 2/26/2022
National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide. (Shaw BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC, Shah NN, Mussetter A, Tang XY, McCarty JM, Alavi A, Farhadfar N, Jamieson K, Hardy NM, Choe H, Ambinder RF, Anasetti C, Perales MA, Spellman SR, Howard A, Komanduri KV, Luznik L, Norkin M, Pidala JA, Ratanatharathorn V, Confer DL, Devine SM, Horowitz MM, Bolaños-Meade J) J Clin Oncol 2021 Jun 20;39(18):1971-1982 PMID 33905264 PMCID: PMC8260905 SCOPUS ID: 2-s2.0-85108386444 4/28/2021
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. (Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, Keever-Taylor CA, Krueger W, Worden AA, Kadan MJ, Yim S, Cunningham A, Hamadani M, Fenske TS, Dropulić B, Orentas R, Hari P) Nat Med 2020 Oct;26(10):1569-1575 PMID: 33020647 DOI: 10.1038/s41591-020-1081-3 SCOPUS ID: 2-s2.0-85092105030 10/07/2020